84946-20-3

Basic information

• Product Name: 1-(4-Fluorobenzyl)-2-chlorobenzimidazole
• Synonyms: 2-Chloro-1-(4-fluorobenzyl)-1H-benzo[d]iMidazole;2-Chloro-1-(4-fluorobenzyl)benzimidazole 97%;N-METHYL-N-(-CHLOROETHYL) ANILINE;3-(4'-FLUOROBENZY)-2-CHLOROBENZIMIDAZOLE;1-(4'-FLUOROBENZYL)-2-CHLOROBENZIMIDAZOLE;1-(4-FLUOROBENZYL)-2-CHLORO-BENZIMIDAZOLE;1-(4-FLUOROPHENYLMETHYL)-2-CHLOROBENZIMIDAZOLE;2-CHLORO-1-(4-FLUOROBENZYL)-1H-BENZIMIDAZOLE
• CAS NO: 84946-20-3
• Molecular Formula: C₁₄H₁₀ClFN₂
• Molecular Weight: 260.69
• EINECS: 284-624-0
• Product Categories: Inhibitors;Intermediates & Fine Chemicals;Pharmaceuticals;PHARMACEUTICAL INTERMEDIATES;Imidazol&Benzimidazole;(intermediate of mizolastine);Aromatics;Heterocycles
• Mol File: 84946-20-3.mol
• Article Data: 20

Chemical Properties

• Melting Point: 83-87 °C(lit.)
• Boiling Point: 432.3 °C at 760 mmHg
• Flash Point: 215.2 °C
• Appearance: /
• Density: 1.3 g/cm³
• Vapor Pressure: 1.12E-07mmHg at 25°C
• Refractive Index: 1.626
• Storage Temp.: Refrigerator
• Solubility: soluble in Methanol
• PKA: 3.42±0.10(Predicted)
• CAS DataBase Reference: 1-(4-Fluorobenzyl)-2-chlorobenzimidazole(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(4-Fluorobenzyl)-2-chlorobenzimidazole(84946-20-3)
• EPA Substance Registry System: 1-(4-Fluorobenzyl)-2-chlorobenzimidazole(84946-20-3)

Safety Data

• Safety Statements: 22-24/25
• WGK Germany: 3
• Hazardous Substances Data: 84946-20-3(Hazardous Substances Data)

Usage

Chemical Properties

White Solid

Uses

A novel aldose reductase (ALR2) inhibitor.

InChI:InChI=1/C14H10ClFN2/c15-14-17-12-3-1-2-4-13(12)18(14)9-10-5-7-11(16)8-6-10/h1-8H,9H2

Upstream product

• 4857-06-1 2-chloro-1H-benzoimidazole 
• 352-11-4 1-chloromethyl-4-fluorobenzene 
• 7191-70-0 N-(4''-fluorobenzyl)-1,2-phenylenediamine 
• 95-54-5 1,2-diamino-benzene 
• 100460-79-5 N-(4''-fluorobenzyl)-2-nitroaniline 
• 88-74-4 2-nitro-aniline 
• 459-46-1 4-Fluorobenzyl bromide 
• 615-16-7 1H-benzimidazol-2-ol 
• 100460-87-5 1-<(4-fluorophenyl)methyl>-benzimidazol-2(3H)-one 

Downstream Products

• 84501-68-8 ethyl 4-[[1-[(4-fluorophenyl)methyl]-1H-benzimidazol-2-yl]amino]-1-piperidinecarboxylate 
• 100460-87-5 1-<(4-fluorophenyl)methyl>-benzimidazol-2(3H)-one 
• 108635-83-2 1-{1-[(4-Fluorophenyl)methyl]-1H-benzimidazol-2-yl}-N-methyl-4-piperidinamine 
• 124443-67-0 1-[(4-fluorophenyl)methyl]-1H-benzimidazole 
• 75970-99-9 norastemizole 

Relevant articles and documents

Antimalarial Benzimidazole Derivatives Incorporating Phenolic Mannich Base Side Chains Inhibit Microtubule and Hemozoin Formation: Structure-Activity Relationship and in Vivo Oral Efficacy Studies

A novel series of antimalarial benzimidazole derivatives incorporating phenolic Mannich base side chains at the C2 position, which possess dual asexual blood and sexual stage activities, is presented. Structure-activity relationship studies revealed that the 1-benzylbenzimidazole analogues possessed submicromolar asexual blood and sexual stage activities in contrast to the 1H-benzimidazole analogues, which were only active against asexual blood stage (ABS) parasites. Further, the former demonstrated microtubule inhibitory activity in ABS parasites but more significantly in stage II/III gametocytes. In addition to being bona fide inhibitors of hemozoin formation, the 1H-benzimidazole analogues also showed inhibitory effects on microtubules. In vivo efficacy studies in Plasmodium berghei-infected mice revealed that the frontrunner compound 41 exhibited high efficacy (98% reduction in parasitemia) when dosed orally at 4 × 50 mg/kg. Generally, the compounds were noncytotoxic to mammalian cells.

Design, synthesis and characterization of novel N-heterocyclic-1-benzyl-1H-benzo[d]imidazole-2-amines as selective TRPC5 inhibitors leading to the identification of the selective compound, AC1903

The transient receptor potential cation channel 5 (TRPC5) has been previously shown to affect podocyte survival in the kidney. As such, inhibitors of TRPC5 are interesting candidates for the treatment of chronic kidney disease (CKD). Herein, we report the synthesis and biological characterization of a series of N-heterocyclic-1-benzyl-1H-benzo[d]imidazole-2-amines as selective TRPC5 inhibitors. Work reported here evaluates the benzimidazole scaffold and substituents resulting in the discovery of AC1903, a TRPC5 inhibitor that is active in multiple animal models of CKD.

A benzimidazole hERG potassium ion channel of small molecule fluorescent probe and its preparation method and application

The invention relates to a benzimidazole hERG potassium ion channel small-molecular fluorescent probe and a preparation method and applications thereof; the fluorescent probe has the structural general formula represented by the formula (I), wherein in the formula, R1 is hydroxyl, halogen, alkyl or alkoxy monosubstituent or polysubstituent, R2 is fluorophore, n is 1-6, particularly, R1 is p-halogen, and R2 is coumarin, naphthalene diimide, NBD, Cy5 or fluorescein isothiocyanate fluorophore. The invention discloses the applications of the probe in marking of hERG potassium ion channels and high-expression tumor cells or tissues, high-throughput screening of hERG potassium ion channel inhibitors, evaluation of new drug cardiotoxicity, use as a probe for identification of the hERG potassium ion channels and studies on hERG potassium ion channel physiological, pathological and related diseases.